Tomoko Iwata Selected Research

hydroxide ion

11/2018

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tomoko Iwata Research Topics

Disease

16	Heart Failure 12/2023 - 01/2021
6	Neoplasms (Cancer) 01/2020 - 10/2005
3	Cardiomyopathies (Cardiomyopathy) 12/2023 - 01/2022
3	Carcinogenesis 01/2018 - 07/2011
2	Atrial Fibrillation 01/2023 - 01/2021
2	Body Weight (Weight, Body) 10/2022 - 01/2021
2	Urinary Bladder Neoplasms (Bladder Cancer) 11/2018 - 06/2014
2	Communicable Diseases (Infectious Diseases) 01/2017 - 01/2015
1	Frailty 12/2023
1	Chronic Renal Insufficiency 01/2023
1	Kidney Diseases (Kidney Disease) 01/2023
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2022
1	Disease Progression 01/2021
1	Inflammation (Inflammations) 11/2018
1	Papilloma (Papillomatosis) 07/2011
1	Carcinoma (Carcinomatosis) 07/2011
1	Neuroblastoma 11/2010
1	Melanoma (Melanoma, Malignant) 07/2006
1	Achondroplasia 01/2004

Drug/Important Bio-Agent (IBA)

14	empagliflozinIBA 12/2023 - 01/2021
4	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2022 - 01/2021
4	pro-brain natriuretic peptide (1-76)IBA 10/2022 - 01/2021
4	Troponin T (Troponin T1)IBA 10/2022 - 01/2021
4	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2020
3	Natriuretic PeptidesIBA 10/2022 - 01/2021
3	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 06/2014 - 01/2004
2	SodiumIBA 12/2023 - 12/2022
2	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2023 - 01/2021
2	SymportersIBA 12/2023 - 12/2022
2	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 12/2022
2	AlbuminsIBA 01/2023 - 10/2022
2	Sodium-Glucose Transport ProteinsIBA 11/2021 - 01/2021
2	VaccinesIBA 01/2017 - 01/2015
1	CreatinineIBA 01/2023
1	Hemoglobins (Hemoglobin)IBA 10/2022
1	Uric Acid (Urate)IBA 10/2022
1	Insulin (Novolin)FDA Link 10/2022
1	Neprilysin (Neutral Endopeptidase)IBA 11/2021
1	sacubitril and valsartan sodium hydrate drug combinationIBA 11/2021
1	TroponinIBA 01/2021
1	DiureticsIBA 01/2021
1	Circulating Tumor DNAIBA 01/2020
1	hydroxide ionIBA 11/2018
1	Phenobarbital (Luminal)FDA Link 11/2018
1	Monoclonal AntibodiesIBA 11/2018
1	CarcinogensIBA 11/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	N2-ethyl-2'-deoxyguanosineIBA 01/2018
1	Liposomes (Liposome)IBA 01/2015
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2014
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2012
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 04/2012
1	CateninsIBA 07/2011
1	Cre recombinaseIBA 07/2011
1	Small Interfering RNA (siRNA)IBA 11/2010
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 11/2010
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2008
1	AntigensIBA 01/2008
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2006
1	CytokinesIBA 07/2006
1	Interleukin-6 (Interleukin 6)IBA 07/2006
1	Interleukin-12 (IL 12)IBA 07/2006
1	U 0126 (UO 126)IBA 07/2006
1	InterleukinsIBA 07/2006
1	LipopolysaccharidesIBA 07/2006
1	Mitogen-Activated Protein KinasesIBA 07/2006
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 10/2005

Therapy/Procedure

1	Polypharmacy 12/2023
1	Patient Readmission 01/2023
1	Therapeutics 10/2022
1	Aftercare (After-Treatment) 01/2020
1	Immunotherapy 01/2008